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Effect of a Proposed Trastuzumab Biosimilar Compared
With Trastuzumab onOverall Response Rate in Patients
With ERBB2 (HER2)–PositiveMetastatic Breast Cancer
A Randomized Clinical Trial
Hope S. Rugo, MD; Abhijit Barve, MD, PhD, MBA; Cornelius F. Waller, MD; Miguel Hernandez-Bronchud, MD, PhD; Jay Herson, PhD; Jinyu Yuan, PhD;
Rajiv Sharma, MBBS, MS; Mark Baczkowski, MS, RPh; Mudgal Kothekar, MD; Subramanian Loganathan, MD; AlexeyManikhas, MD; Igor Bondarenko, MD;
Guzel Mukhametshina, MD; Gia Nemsadze, MD, PhD; Joseph D. Parra, MD; Maria Luisa T. Abesamis-Tiambeng, MD; Kakhaber Baramidze, MD, PhD;
Charuwan Akewanlop, MD; Ihor Vynnychenko, MD; Virote Sriuranpong, MD; GopichandMamillapalli, MS, MCh; Sirshendu Ray, MS;
Eduardo P. Yanez Ruiz, MD; Eduardo Pennella, MD, MBA; for the Heritage Study Investigators
IMPORTANCE Treatmentwith the anti-ERBB2 humanizedmonoclonal antibody trastuzumab
and chemotherapy significantly improves outcome in patientswith ERBB2 (HER2)–positive
metastatic breast cancer; a clinically effective biosimilarmay help increase access to this therapy.
OBJECTIVE To compare the overall response rate and assess the safety of a proposed
trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without prior
treatment for ERBB2-positive metastatic breast cancer.
DESIGN, SETTING, AND PARTICIPANTS Multicenter, double-blind, randomized, parallel-group,
phase 3 equivalence study in patients with metastatic breast cancer. FromDecember 2012 to
August 2015, 500 patients were randomized 1:1 to receive a proposed biosimilar or
trastuzumab plus a taxane. Chemotherapy was administered for at least 24 weeks followed
by antibody alone until unacceptable toxic effects or disease progression occurred.
INTERVENTIONS Proposed biosimilar (n = 230) or trastuzumab (n = 228) with a taxane.
MAIN OUTCOMES ANDMEASURES The primary outcomewasweek 24 overall response rate
(ORR) defined as complete or partial response. Equivalence boundaries were 0.81 to 1.24
with a 90%CI for ORR ratio (proposed biosimilar/trastuzumab) and −15% to 15%with a 95%
CI for ORR difference. Secondary outcomemeasures included time to tumor progression,
progression-free and overall survival at week 48, and adverse events.
RESULTS Among500women randomized, the intention-to-treat population included458
women (mean [SD] age, 53.6 [11.11] years) and the safetypopulation included493women.
TheORRwas69.6%(95%CI, 63.62%-75.51%) for theproposedbiosimilar vs64.0%(95%CI,
57.81%-70.26%) for trastuzumab. TheORR ratio (1.09;90%CI,0.974-1.211) andORRdifference
(5.53; 95%CI, −3.08 to 14.04)werewithin theequivalenceboundaries. Atweek48, therewasno
statistically significant differencewith theproposedbiosimilar vs trastuzumab for time to tumor
progression (41.3%vs43.0%;−1.7%;95%CI, −11.1% to6.9%), progression-free survival (44.3%
vs44.7%;−0.4%;95%CI, −9.4%to8.7%), or overall survival (89.1%vs85.1%;4.0%;95%CI,
−2.1% to 10.3%). In theproposedbiosimilar and trastuzumabgroups, 239 (98.6%)and233
(94.7%)hadat least 1 adverse event, themost common includingneutropenia (57.5%vs53.3%),
peripheral neuropathy (23.1%vs24.8%), anddiarrhea (20.6%vs20.7%).
CONCLUSIONS AND RELEVANCE Amongwomenwith ERBB2-positivemetastatic breast cancer
receiving taxanes, the use of a proposed trastuzumab biosimilar compared with trastuzumab
resulted in an equivalent overall response rate at 24 weeks. Further study is needed to assess
safety and long-term clinical outcome.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT02472964; EudraCT Identifier:
2011-001965-42
JAMA. doi:10.1001/jama.2016.18305
Published online December 1, 2016.
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B iological agents, includingmonoclonalantibodies,haveincreased the treatment options and greatly im-proved outcomes for a number of cancers.1,2 How-
ever, patient access to these biologics is limited in many
countries.3-5 With impending patent expiration of some bio-
logical agents, development of biosimilars has become a high
priority for drug developers and health authorities through-
out the world to provide access to high-quality alternatives.6
Trastuzumab combined with chemotherapy has mark-
edly improved response, progression-free survival (PFS), and
overall survival forERBB2 (formerlyhumanepidermal growth
factor receptor 2 [HER2] or HER2/neu)–positive metastatic
breast cancer and improved survival in early-stage ERBB2-
positive breast cancer7-9 and metastatic ERBB2-positive gas-
tric cancer compared with chemotherapy alone.10 The effi-
cacy and safety of the proposed trastuzumab biosimilar were
evaluated based on a stepwise approach of physicochemical
and biological characterization, nonclinical, pharmacoki-
netic, and pharmacodynamic studies.11 This phase 3 confir-
matory clinical study (Heritage Study) compared the effi-
cacy, safety, and immunogenicity of the proposed biosimilar
in combination with a taxane vs the reference drug trastu-
zumab in combinationwith a taxane inpatientswithmeasur-
able ERBB2-positive metastatic breast cancer.
Methods
Heritage Study Design andObjectives
This was amulticenter, international, double-blind, random-
ized, parallel-group, phase 3 studycomparing theefficacy and
safety of a proposed trastuzumab biosimilar plus a taxane
(docetaxel or paclitaxel by physician choice) vs trastuzumab
plusa taxane inpatientswithERBB2-positivemetastaticbreast
cancer (part 1) (Figure), with continuation of either the pro-
posed biosimilar or trastuzumab for participants who had at
least stable disease to evaluate continued safety and immu-
nogenicity (part 2). In part 1, patientswere randomized in a 1:1
ratio to the 2 treatment groups within 3 days prior to cycle 1
(day 1). After completing a minimum of 8 cycles (24 weeks),
participants with at least stable disease (based on radio-
graphic tumor assessments and clinical evaluation) were eli-
gible for part 2. In part 2, patients continued to receive their
originally allocated treatment until the occurrence of disease
progression, unacceptable toxic effects, or death. The results
ofpart 1of this24-weekstudyarepresented togetherwith time
to tumor progression (TTP), PFS, and overall survival for pa-
tients with 48weeks of follow-up. The complete results from
part 2 will be presented in a future publication.
This studywas conducted in accordancewith the Interna-
tional Council for Harmonisation of Technical Requirements
for Pharmaceuticals forHumanUse tripartite guideline on the
ethical principles of good clinical practice (guideline E6) and
applicable regulatory requirements including the archiving of
essential documents. All study patients provided written in-
formedconsent,andpatientswithbreastcancer treatedatstudy
siteshad theopportunity todeclineparticipation.The full trial
protocol (available in Supplement 2), the patient information
and consent form, and other relevant study documentation
wereapprovedby the institutional reviewboardorethics com-
mittee at each study center before initiation of the study. In-
formedconsentwasobtained inwriting fromall studypartici-
pants prior to enrollment.Race andethnicitywere reported as
part of standardpatient demographic data andwere classified
by the investigator usingpredefinedoptions, includingAsian,
black/African American, Caucasian, Native Hawaiian/Pacific
Islander, American Indian/Alaskan Native, and other.
Eligibility
Eligible patients were male or female with breast cancer that
was measurably ERBB2 positive (defined as central labora-
tory documentation of ERBB2-positive overexpression by
immunohistochemistry [IHC], ie, IHC3+, or IHC2+ with fluo-
rescent in situ hybridization confirmation [ratio >2]) without
prior exposure to chemotherapy or trastuzumab in the
metastatic setting. Additional eligibility criteria included an
Eastern Cooperative Oncology Group (ECOG) Performance
Status of 0 to 2, left ventricular ejection fraction (LVEF)
within institutional range of normal, and at least 1 year since
adjuvant therapy with trastuzumab. Patients with newly
detected central nervous system metastases had to have
stable disease following treatment (eg, radiotherapy, stereo-
tactic radiosurgery). Hormonal agents had to be discontinued
before beginning study therapy. The full inclusion and exclu-
sion criteria are listed in the trial protocol in Supplement 2.
Exclusion criteria included a history of unstable angina,
heart failure, myocardial infarction less than 1 year from ran-
domization,orotherclinicallysignificantcardiacdisease,grade
2 or higher peripheral neuropathy according to the National
Cancer Institute Common Terminology Criteria for Adverse
Eventsversion4.03,ahistoryofanyothercancerwithin5years
prior to screeningwith the exceptionof in situ cancers or non-
melanomatous skin cancers, or significantmedical illness that
would increase the risk of treatment or impede evaluation of
response in the judgment of the treatment physician.
Treatment
Patientswere randomized ina 1:1 ratio to theproposedbiosimi-
lar plus a taxaneor to trastuzumabplus a taxane.A centralized
randomization procedure was used with preallocated blocks.
Key Points
Question Are the effects of a proposed trastuzumab biosimilar
equivalent to those of trastuzumab in the treatment of ERBB2
(formerly HER2 or HER2/neu)–positive metastatic breast cancer?
Findings In this randomized clinical trial that included458women,
the overall response rate to the proposed biosimilar plus a taxane at
24weekswas 69.6% (95%CI, 63.62%-75.51%) comparedwith
64.0% (95%CI, 57.81%-70.26%) for trastuzumabplus a taxane,
whichwaswithin predefined equivalence boundaries.
Meaning Although further assessment is needed to establish
long-term clinical outcomes and safety, the availability of a clinically
effective biosimilar treatment option for trastuzumabmay lead to
broader access to this therapy for patientswith breast cancer.
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Ablocking size of 8was used in the treatment assignment. Pa-
tients were stratified at randomization based on 3 factors, in-
cludingtumorprogressiontometastaticphasein2orfeweryears
or more than 2 years after primary diagnosis, centrally deter-
mined estrogen receptor and progesterone receptor status
(≥1 positive or both negative), and type of taxane; each factor
consistedof 2 levels, resulting in a total of 8 stratification com-
binations. Treatment allocation was blinded using an interac-
tive voice response or interactive web response system.
Trastuzumab (Herceptin; Roche Pharma AG) or the pro-
posedbiosimilar (MYL-1401O;Mylan)was administered as an
intravenous infusion every 3 weeks. An initial 8-mg/kg load-
ing dosewas administered over 90minutes, followed by dos-
ing every 3 weeks of 6 mg/kg over 30 minutes.
The choice of taxane (docetaxel or paclitaxel) was by in-
vestigatordecisionat each study site andwasapplied to all pa-
tients enrolled at that site. Docetaxel was administered at
75 mg/m2 every 3 weeks and paclitaxel at 80 mg/m2 weekly.
Paclitaxel could be omitted by investigator choice for 1 week
every 4 weeks.
Theproposedbiosimilarplusa taxaneor trastuzumabplus
a taxanewasadministered foraminimumof8treatmentcycles
(1 treatment cycle = 3 weeks based on trastuzumab adminis-
tration) unless the participant experienced unacceptable ad-
verse effects, had disease progression, or was prematurely
withdrawn from treatment. In patients with responding or
stable disease, chemotherapy could be discontinued after 8
treatment cycles; trastuzumab was continued every 3 weeks
until disease progression occurred.
Tumor assessments were conducted every 6 weeks.
Computed tomography or magnetic resonance imaging of
the chest and upper abdomen and, if clinically indicated,
bone and/or brain imaging were performed to quantify dis-
ease burden. Images were sent electronically to Parexel
Figure. Flow of Patients Through the Trial
826 Screened for eligibility a
326 Did not meet eligibility criteria b
289 Did not meet inclusion criteria
32 Met exclusion criteria c
6 History of serious cardiac disease
6 Serious medical illness
5 Other (early death or withdrawal
of consent)
45 Laboratory test results outside
of range for inclusion
122 Breast cancer ERBB2 negative
58 No measurable metastatic breast
cancer lesion
500 Randomized
230 Included in primary analysis
(intention-to-treat population)
2 Did not receive treatment
228 Included in primary analysis
(intention-to-treat population)
4 Did not receive treatment
19 Excluded (ineligible after study
protocol amendment d)
23 Excluded (ineligible after study
protocol amendment d)
173 Completed 24 wk of treatment
55 Discontinued treatment prior
to 24 wk
4 Adverse event
41 Disease progression
6 Death
1 Investigator or sponsor
decision
1 Lost to follow-up
1 Withdrew consent
1 Other
159 Completed 24 wk of treatment
65 Discontinued treatment prior
to 24 wk
2 Adverse event
51 Disease progression
3 Death
1 Investigator or sponsor
decision
7 Withdrew consent
1 Other
249 Randomized to receive proposed
biosimilar + taxane
247 Received treatment as
randomized
2 Did not receive treatment
as randomized
1 Died
1 Lost to follow-up
251 Randomized to receive
trastuzumab + taxane
247 Received treatment as
randomized
4 Did not receive treatment
as randomized
2 Withdrew consent
2 Other
a Nine patients were rescreened
(only counted once in the total
number of patients screened).
bAll reasons for screening failures
were not reported by all study sites.
c Exclusion criteria included a history
of unstable angina, heart failure,
myocardial infarction less than
1 year from randomization, or other
clinically significant cardiac disease,
grade 2 or higher peripheral
neuropathy according to the
National Cancer Institute Common
Terminology Criteria for Adverse
Events version 4.03, a history of any
other cancer within 5 years prior to
screening with the exception of
in situ cancers or nonmelanomatous
skin cancers, or serious medical
illness that would increase the risk
of treatment or impede evaluation
of response in the judgment of the
treatment physician.
d Protocol amendment changed
eligibility criteria to exclude patients
who had already received first-line
therapy. This allowed performance
of the primary efficacy analyses in a
homogeneous patient population.
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Informatics, and tumor measurements were performed by
blinded reviewers using Response Evaluation Criteria in Solid
Tumors (RECIST) version 1.1 criteria. Responses were con-
firmed with a second tumor assessment at least 4 weeks after
the first response.
End Points
The primary end point was to compare the objective overall
response rate (ORR), defined as complete or partial response
by RECIST version 1.1 criteria12 at week 24.
Secondary end points analyzed at week 48 included TTP,
defined as the time from randomization to the date of first
documentation of objective progression; PFS, defined as the
time from randomization to first documentation of objective
progression or to death due to any cause; and overall sur-
vival, defined as the time from randomization to the date of
deathdue toanycause.Analysesof thesesecondaryendpoints
were not adjusted formultiplicity and should therefore be in-
terpreted as exploratory.
Other end points evaluated at both 24 and 48 weeks
included adverse events, laboratory assessments, LVEF, and
immunogenicity. Population pharmacokinetic end points
included area under the curve, maximum drug concentra-
tion, and minimum drug concentration. All end point assess-
ments were blinded to group assignment.
The investigator was responsible for the detection and
documentation of events meeting the criteria and definition
of an adverse event. At each visit the participantwas asked to
report any issues, and the investigator evaluated and moni-
toredanyreportedevent.Clinically relevantobservationsmade
by the investigator during the visitwere also considered to be
an adverse event. Treatment-emergent adverse events, de-
fined as events that began or worsened at or after treatment
with the investigational drug andonorwithin 28days follow-
ing the last dose of investigational drug, were the adverse
events of interest in this study.
Table 1. Patient Demographic Characteristics, Disease History,
and Baseline Characteristics in the Intention-to-Treat Population
Characteristic
Proposed
Biosimilar + Taxane
(n = 230)
Trastuzumab +
Taxane
(n = 228)
Age
Mean (SD), y 54.3 (10.97) 52.9 (11.22)
Median (range), y 55.0 (26-79) 54.0 (26-82)
<50 y, No. (%) 74 (32.2) 86 (37.7)
≥50 y, No. (%) 156 (67.8) 142 (62.3)
Race, No. (%)
Asian 70 (30.4) 72 (31.6)
Black or African American 1 (0.4) 2 (0.9)
White 159 (69.1) 154 (67.5)
Previous treatment,
No. (%)
Trastuzumab 22 (9.6) 16 (7.0)
Taxane 46 (20.0) 42 (18.4)
Assigned taxane,
No. (%)
Docetaxel 193 (83.9) 192 (84.2)
Paclitaxel 35 (15.2) 32 (14.0)
No treatment 2 (0.9) 4 (1.8)
Tumor endocrine status,
No. (%)
ER and PR negative 128 (55.7) 127 (55.7)
ER and/or PR positive 102 (44.3) 101 (44.3)
ECOG Performance Status,
No. (%)a
(n = 247) (n = 246)
0 127 (51.4) 107 (43.5)
1 115 (46.6) 132 (53.7)
2 5 (2.0) 6 (2.4)
Missing 0 1 (0.4)
LVEF, %a (n = 246) (n = 244)
Mean (SD) 64.0 (5.79) 64.1 (5.71)
Median (range) 64.0 (51-82) 63.0 (51-84)
ADA, No. (%)a (n = 247) (n = 246)
Positive 14 (5.7) 22 (8.9)
Negative 233 (94.3) 224 (91.1)
Antibody titerb
Mean (95% CI) 2.8 (1.7-3.9) 2.5 (1.8-3.2)
Median (range) 2.2 (1-7.1) 2.3 (1-6.9)
ERBB2 ECD, No. (%)
<15 ng/mL 60 (26.1) 46 (20.2)
≥15 ng/mL 162 (70.4) 172 (75.4)
Missing 8 (3.5) 10 (4.4)
Time from initial diagnosis
to metastatic disease,
No. (%)
<2 y 146 (63.5) 153 (67.1)
≥2 y 75 (32.6) 71 (31.1)
Missing 9 (3.9) 4 (1.8)
No. of metastatic sites,
No. (%)
1 58 (25.2) 61 (26.8)
2 87 (37.8) 67 (29.4)
3 44 (19.1) 57 (25.0)
≥4 41 (17.8) 43 (18.9)
(continued)
Table 1. Patient Demographic Characteristics, Disease History,
and Baseline Characteristics in the Intention-to-Treat Population
(continued)
Characteristic
Proposed
Biosimilar + Taxane
(n = 230)
Trastuzumab +
Taxane
(n = 228)
Presence of visceral metastases,
No. (%)
Yes 172 (74.8) 185 (81.1)
No 58 (25.2) 43 (18.9)
CNS as first site of metastasis,
No. (%)
Yes 1 (0.4) 2 (0.9)
No 229 (99.6) 226 (99.1)
Abbreviations: ADA, antidrug antibody; CNS, central nervous system;
ECD, extracellular domain; ECOG, Eastern Cooperative Oncology
Group; ER, estrogen receptor; LVEF, left ventricular ejection fraction;
PR, progesterone receptor.
a Sample sizes are the numbers of patients with available data within the
treatment group.
b The titer value corresponds to the highest dilution of a sample that yields a
positive result in the assay.
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Statistical Analysis
Theprimary efficacy analysiswas conducted in the intention-
to-treat (ITT) population (all patients randomized after
the amendment as defined in the Figure). Patients with
missing data or who were lost to follow-up were categorized
based on best response at 24 weeks or at the time of the last
tumor assessment. If no response data were available, pa-
tients were included as nonresponders. The safety popula-
tion included all participants who received at least 1 dose of
study drug in any amount.
The pharmacokinetic population included all randomized
patientswhoreceivedat least 1completedoseofstudydrugand
who provided at least 1 postdose sample for pharmacokinetic
analysis. The population pharmacokinetic analysis was based
on the pharmacokinetic population. A population pharmaco-
kinetic model was developed using a 2-compartment linear
model including assessment of covariate effects on the inter-
individual variability in pharmacokinetic parameters. The ef-
fect of ERBB2 extracellular domain on trastuzumab pharma-
cokinetic levelswas evaluated as part of the primary covariate
analysis. Observedminimumdrug concentrationvalues at the
end of cycle 1 and cycle 6 were used to assess the similarity of
the proposed biosimilar vs trastuzumab using the 2 one-sided
t tests statistical approach for bioequivalence.
SASversion9.3 statistical software (SAS Institute Inc)was
used to analyze thedata from this study. The statistical analy-
sis plan is provided in Supplement 3.
Primary Efficacy Analysis
The primary efficacy end point was ORR based on central
imaging evaluation. Per US Food and Drug Administration
(FDA) recommendation (internalwrittencommunicationwith
FDA, April 25, 2012), the equivalence analysis was based on
the ratio of ORRs with a 90% confidence interval. To com-
pare theprimaryefficacyendpoint for the2 treatmentgroups,
the ratio of the ORRs at week 24 was assessed for statistical
significance.
A 2-sided 90% confidence interval for the ratio of ORRs
at week 24 was calculated based on the method of logarith-
mic transformation with no adjustment for covariates. The
2-sided 90% confidence interval was equivalent to 2 one-
sided tests at the5%level.Equivalencewasdeclared if thecon-
fidence intervalwas completelywithin the equivalence range
of0.81 to 1.24.A2-sided95%confidence intervalwas also cal-
culated for exploratory purposes.
TheEuropeanMedicinesAgency (EMA) requested that the
difference in ORRs be used as the primary efficacy analysis,
using a 95% confidence interval (internal written communi-
cation with EMA, March 15, 2013). A 2-sided 95% confidence
interval for the difference of the ORRs at week 24 was calcu-
lated. Equivalencewasdeclared if the confidence intervalwas
completely within the equivalence range of −15% to 15%.
The equivalence margins for ORR were derived based on
meta-analysisofORRfromprevious randomized trials.13-15The
final clinical justificationwasdeterminedby relatingORRwith
PFS using the weighted least squares regression model.
Through the weighted least squares regression model, the
boundaries of the equivalencemargins correspond to adevia-
tion of 1.9 months or less from a median PFS of 12 months,
which was not considered to be clinically meaningful.
Secondary Efficacy Analysis
Secondary end points included TTP, PFS (centrally con-
firmed), andoverall survival (investigatorassessed)atweek48.
Kaplan-Meier plots by treatment and the unadjusted log-rank
test for any covariates were performed. Cox proportional
hazards model was used to analyze for treatment effects, ad-
justing for subgroup. Univariate analysis and multivariate
analysis with forward selection were performed. Hazard ra-
tios and 95% confidence intervals were calculated.
Sample Size Calculation
PerFDA recommendation, the equivalence analysiswasbased
on the ratio of ORRs using historical randomized trastuzumab
trials13-15 with a fixed-effects meta-analysis (statistical analy-
sis plan in Supplement 3) to estimate the treatment effect of
trastuzumab plus chemotherapy vs chemotherapy alone.
Samplesizesof410patients for theFDA-recommendedend
point and 400 patients for the EMA-recommended end point
were required toprovideat least80%power todeclare thepro-
posed biosimilar equivalent to trastuzumab in the analysis of
ORR atweek 24. These sample sizes assumed that both treat-
ment groups would exhibit an ORR of 69% at week 24,16 that
the ratio of ORR for the proposed biosimilar to trastuzumab
wouldbeanalyzedwitha2-sided90%confidence interval, and
thatthedifferencebetweenthe2groupswouldbeanalyzedwith
a 2-sided95%confidence interval. Therefore, a sample size of
410patientswaschosentosatisfy therecommendationsofboth
regulatory agencies for equivalence analysis. To arrive at the
plannednumberofpatients, therequiredsamplesizeof410was
increased to 456 to reflect an estimated 10% attrition rate.
Additional Analysis
Adescriptionof thesecondaryefficacyanalysis, includingTTP,
PFS, overall survival, immunogenicity, population pharma-
cokinetics, andsafety, isprovided in thestatistical analysisplan
(Supplement 3). Sensitivity and exploratory analyses are also
described in the statistical analysis plan (Supplement 3).
To evaluate site-specific effects, an unplanned mixed-
effect analysiswasperformed.Specifically, thegeneralized lin-
ear mixed model (Proc GLIMMIX in SAS) was fit with ORR as
the responsevariable, site as randomeffect, and theother fac-
tors or covariates (treatment, age, race, previous adjuvant or
neoadjuvant chemotherapy or HER2-targeted treatment [yes
or no], number of visceral metastases, number of metastatic
sites, central nervous system as first site of metastasis, and
stratification factor) as fixed effects.
Protocol Amendment
Aprotocol amendment changedeligibility criteria after 42pa-
tients were enrolled to exclude patients who had already re-
ceived first-line therapy based on steering committee recom-
mendations to include a homogeneous patient population.
These patients were excluded from the primary ITT analysis
population (see protocol amendments in the trial protocol in
Supplement 2).
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Results
Patient Demographics, Disease History,
and Baseline Characteristics
Ata total of95 sites inBulgaria,Chile,CzechRepublic,Georgia,
Hungary, India, Latvia, Philippines, Poland,Romania, Russia,
Serbia, Slovakia, SouthAfrica, Thailand, andUkraine, 500pa-
tientswith ERBB2-positivemetastatic breast cancerwere en-
rolled between December 10, 2012, and August 5, 2015 (last
follow-up visit January 25, 2016) (Figure). Forty-two patients
(proposed biosimilar, n = 19; trastuzumab, n = 23) were ex-
cluded as ineligible after the protocol amendment. The num-
ber of patients enrolled per site ranged from 1 to 28 (median,
3patients; interquartile range, 5patients [25thpercentile, 2pa-
tients; 75th percentile, 7 patients]) (eTable in Supplement 1).
Demographic characteristics were similar for patients in the
proposed trastuzumab biosimilar and trastuzumab groups.
Disease history andbaseline characteristicswere comparable
in both treatment groups and no clinically relevant differ-
ences were observed (Table 1).
Among the 458 women in the ITT population, the mean
(SD) age was 53.6 (11.11) years (median age, 55 years; range,
26-82years),withamedianageof55years (range, 26-79years)
for the proposed biosimilar group and 54 years (range, 26-82
years) for the trastuzumabgroup.Themajorityofpatientswere
white (69.1% in theproposedbiosimilar groupvs 67.5% in the
trastuzumab group), followed by Asian (30.4% in the pro-
posedbiosimilar groupvs31.6% in the trastuzumabgroup).All
patients were female.
Tumors were estrogen receptor negative and progester-
one receptor negative in 55.7% of patients in both treatment
groups. A higher percentage of patients in the proposed bio-
similar grouphadanECOGPerformance Status of0 compared
with the trastuzumab group (51.4% vs 43.5%, respectively).
AmongpatientswithERBB2extracellulardomainvaluesavail-
able, baseline values for ERBB2 extracellular domain were
higher in the trastuzumabgroup comparedwith theproposed
biosimilargroup (ERBB2extracellulardomain≥15ng/mL in162
of 222patients [73.0%] in theproposedbiosimilar groupvs 172
of 218 patients [78.9%] of the trastuzumab group). Stratifica-
tion of patients at randomization by type of taxane resulted in
similar distribution between treatment groups of docetaxel
(83.9% in the proposed biosimilar group and 84.2% in the
trastuzumabgroup) andpaclitaxel (15.2% in theproposedbio-
similar group and 14.0% in the trastuzumab group).
Patient Disposition
Of the 230 patients in the ITT population randomized to the
proposedbiosimilar group, 173 (75.2%)completedall 24weeks
of therapy. Patient disposition is summarized in theFigure.Of
the 228 patients in the trastuzumab group in the ITT popula-
tion, 159 (69.7%) completed 24 weeks of therapy. In the pro-
posedbiosimilarandtrastuzumabgroups, respectively, thepri-
maryreasonfordiscontinuationwasdiseaseprogression(17.8%
vs 22.4%), followed by withdrawal of consent (0.4% vs 3.1%)
and death (2.6% vs 1.3%). In the ITT population, only 1.7% of
participants in theproposedbiosimilar group and0.9% in the
trastuzumab group discontinued owing to an adverse event.
Primary Efficacy Analysis
The results of the primary efficacy analysis are summarized
in Table 2. The ORRwas 69.6% (160 of 230 patients) (95% CI,
63.62%-75.51%) in the proposed biosimilar group and 64.0%
(146 of 228 patients) (95% CI, 57.81%-70.26%) in the trastu-
zumab group.
The ratio of theORR (proposed biosimilar to trastuzumab)
was 1.09 (90%CI,0.974-1.211). The90%CIwaswithin thepre-
defined equivalence boundaries of 0.81 to 1.24, consistent
with statistical therapeutic equivalenceofproposedbiosimilar
and trastuzumab. For the same ratio of 1.09, the 95%CI of the
ORR ratio between proposed biosimilar and trastuzumab,
Table 2. Primary Outcome: Ratio and Difference of Overall Response Rate atWeek 24 in the Intention-to-Treat Population
Responsea
Proposed
Biosimilar + Taxane
(n = 230)
Trastuzumab + Taxane
(n = 228) Difference, % Rate Ratio
Response type, No. (%)
Complete 3 (1.3) 0
Partial 157 (68.3) 146 (64.0)
Stable disease 48 (20.9) 49 (21.5)
Progressive disease 9 (3.9) 20 (8.8)
Not evaluable 13 (5.7) 13 (5.7)
Overall response rate
Overall response, No. (%)b 160 (69.6) 146 (64.0) 5.53c 1.09d
90% CI, % 64.57 to 74.56 58.81 to 69.26 −1.70 to 12.69 0.974 to 1.211
95% CI, % 63.62 to 75.51 57.81 to 70.26 −3.08 to 14.04 0.954 to 1.237
a Response criteriawere basedonResponseEvaluationCriteria in Solid Tumors
version 1.1 criteria. Complete response indicates disappearance of all target
lesions; partial response, at least a 30%decrease in the sumof the longest
diameter of target lesions, taking as reference thebaseline sum longest
diameter; stable disease, neither sufficient shrinkage to qualify for partial
response nor sufficient increase to qualify for progressive disease, taking as
reference the smallest sum longest diameter since the treatment started; and
progressive disease, at least a 20% increase in the sumof the longest diameter of
target lesions, taking as reference the smallest sum longest diameter recorded
since the treatment started or the appearance of 1 ormore new lesions.
bOverall response includes complete and partial response.
c EuropeanMedicines Agency–recommended analysis.
dUS Food and Drug Administration–recommended analysis.
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calculated for exploratory purposes, was 0.954 to 1.237, also
within the equivalence boundaries.
The difference in ORR (proposed biosimilar minus trastu-
zumab)was5.53 (95%CI, −3.08 to 14.04). This 95%CIwas also
withinthepredefinedequivalenceboundariesof−15%and15%,
consistent with statistical therapeutic equivalence of pro-
posed biosimilar and trastuzumab per EMA recommendation.
The primary efficacy analysis for ORRwas also replicated
intheperprotocolpopulation (n = 438).Theratiobetweenboth
treatment groups (proposed biosimilar to trastuzumab) was
1.06 (90% CI, 0.954 to 1.178).
Secondary Efficacy Analyses
The 48-week exploratory findings of the secondary efficacy
analysis are summarized in Table 3.
Time to Tumor Progression
In the proposed biosimilar group, 95 patients (41.3%) had tu-
morprogressionatweek48comparedwith98patients (43.0%)
in the trastuzumab group. According to the log-rank test, this
difference was not statistically significant (−1.7%; 95% CI,
−11.1% to 6.9%; P = .68). Hazard ratios for TTP for the pro-
posedbiosimilar groupcomparedwith the trastuzumabgroup
by Cox proportional hazards model were 0.94 (95% CI, 0.712
to 1.254) (unstratified) and0.92 (95%CI,0.692 to 1.231) (strati-
fied). There was no statistically significant difference in TTP
between the proposed biosimilar and trastuzumab groups.
Progression-Free Survival
In PFS, the rate of events at week 48 for the proposed bio-
similar group was 44.3% compared with 44.7% for trastu-
zumab, a difference of −0.4% (95% CI, −9.4% to 8.7%;
P = .84) by log-rank test. Hazard ratios for PFS for the pro-
posed biosimilar group compared with the trastuzumab
group obtained from the Cox proportional hazards model
were 0.97 (95% CI, 0.740 to 1.282) (unstratified) and 0.95
(95% CI, 0.714 to 1.251) (stratified). There was no statistically
significant difference in PFS between the proposed biosimilar
and trastuzumab groups.
Overall Survival
Regardingoverallsurvival, intheproposedbiosimilargroup,205
patients (89.1%) survived at week 48 compared with 194 pa-
tients (85.1%) in the trastuzumabgroup; thisdifferenceof4.0%
(95% CI, −2.1% to 10.3%; P = .13) was not statistically signifi-
cant by log-rank test.Hazard ratios for theproposedbiosimilar
groupcomparedwith thetrastuzumabgroupobtainedfromthe
Cox proportional hazards model were 0.67 (95% CI, 0.402 to
1.129) (unstratified) and 0.61 (95% CI, 0.360 to 1.039) (strati-
fied). At 48 weeks, more than 50% of patients had not shown
progression; therefore, the median in the time event efficacy
parameters may be longer at longer data cutoff.
ThemedianKaplan-Meier estimates forTTPandPFSat48
weeks were 11.1 months for both groups. At 48 weeks, fewer
than50%patientshaddiseaseprogression; therefore, theme-
dian in the time event efficacy parameters may be longer in
lateranalyses.Themedian foroverall survivalwasnot reached.
Additional Analysis
The results of an unplanned mixed-effect analysis to evalu-
ate site effects indicated that the covariance parameter esti-
mateof randomeffect sitewas0andthat therewasnotenough
Table3. SecondaryOutcomes: Time toTumorProgression,Progression-FreeSurvival, andOverall Survival atWeek48 in the Intention-to-TreatPopulation
Outcome
Proposed
Biosimilar + Taxane
(n = 230)
Trastuzumab +
Taxane
(n = 228) Log-Rank P Value
Unstratified Stratifieda
Hazard Ratio (95% CI)b P Value Hazard Ratio (95% CI)b P Value
Time to Tumor Progressionc
Events, No. (%) 95 (41.3) 98 (43.0) .68 0.94 (0.71-1.25) .69 0.92 (0.69-1.23) .58
Censored events, No. (%)d 135 (58.7) 130 (57.0)
Kaplan-Meier estimate,
median (95% CI), mo
11.1 (8.83-11.20) 11.1 (8.88-11.20)
Progression-Free Survivale
Events, No. (%) 102 (44.3) 102 (44.7) .84 0.97 (0.74-1.28) .85 0.95 (0.71-1.25) .69
Censored events, No. (%)d 128 (55.7) 126 (55.3)
Kaplan-Meier estimate,
median (95% CI), mo
11.1 (8.81-11.20) 11.1 (8.60-11.20)
Overall Survivalf
Events, No. (%) 25 (10.9) 34 (14.9) .13 0.67 (0.40-1.13) .13 0.61 (0.36-1.04) .07
Censored events, No. (%)d 205 (89.1) 194 (85.1)
Kaplan-Meier estimate,
median (95% CI), mo
Not estimable Not estimable
a Stratified by assigned taxane, tumor progression, and tumor endocrine
status. The sample size for both the proposed biosimilar and trastuzumab
groups was 220.
bThehazardratioestimateswereobtainedfromtheCoxproportionalhazardsmodel.
A hazard ratio less than 1.0 indicates a lower average event rate and a longer
progression-free survival for theproposedbiosimilar relative to trastuzumab.
c Defined as the time from randomization to the date of first documentation of
objective progression, divided by (365.25/12).
d Events not occurring before the data cutoff were censored at the date of
cutoff or the date of the last tumor assessment.
e Defined as the time from randomization to first documentation of objective
progression or to death due to any cause, divided by (365.25/12).
f Defined as the time from randomization to the date of death due to any cause,
divided by (365.25/12).
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variation of response to attribute variation to random effect,
controlling for everything else in themodel. In addition, type
III test results showed that all fixed effects in themodel were
not significant, with P > .11.
Population Pharmacokinetic Analysis
In the pharmacokinetic population, the mean concentrations
of trastuzumab from the 2 treatments were similar (eFigure
in Supplement 1). Trough (minimum) drug concentrations
were comparable between the treatment groups at cycle 6
(week 15). In the proposed biosimilar and trastuzumab
groups, geometric least squares means were 34.011 and
32.740 μg/mL, respectively, with a ratio of 103.88% (90% CI,
93.7%-115.11%). Dose-normalized mean maximum drug con-
centrations were 0.4321 and 0.4196 μg/mL/mg, respectively,
while dose-normalized mean areas under the curve were
98.350 and 94.391 μg · d/mL/mg, respectively, with a coeffi-
cient of variation ranging from 21.87% to 31.06%; both of
these parameters were comparable.
Safety Evaluation
Extent of Exposure
The extent of exposure was similar between the 2 treatment
groups in terms of dose and duration of exposure. The mean
(SD) loading dose was 8.0 (0) mg/kg in both treatment groups
with similar subsequent dose intensity (2.011 mg/kg/wk for
Table 4. Treatment-Emergent Adverse Events and Serious Adverse Events byWeek 24 in the Overall Safety
Population
Event
Participants, No. (%)
Proposed
Biosimilar + Taxane
(n = 247)
Trastuzumab + Taxane
(n = 246)
Overall
(n = 493)
Treatment-Emergent Adverse Eventsa
≥1 Treatment-emergent adverse event 239 (96.8) 233 (94.7) 472 (95.7)
CTCAE preferred term
Alopecia 142 (57.5) 135 (54.9) 277 (56.2)
Neutropenia 142 (57.5) 131 (53.3) 273 (55.4)
Peripheral neuropathy 57 (23.1) 61 (24.8) 56 (23.9)
Diarrhea 51 (20.6) 51 (20.7) 102 (20.7)
Asthenia 54 (21.9) 40 (16.3) 94 (19.1)
Leukopenia 42 (17.0) 51 (20.7) 93 (18.9)
Nausea 49 (19.8) 34 (13.8) 83 (16.8)
Anemia 40 (16.2) 40 (16.3) 80 (16.2)
Peripheral edema 35 (14.2) 28 (11.4) 63 (12.8)
Fatigue 28 (11.3) 33 (13.4) 61 (12.4)
Pyrexia 21 (8.5) 30 (12.2) 51 (10.3)
Myalgia 23 (9.3) 23 (9.3) 46 (9.3)
Vomiting 26 (10.5) 19 (7.7) 45 (9.1)
Decreased appetite 21 (8.5) 24 (9.8) 45 (9.1)
Rash 21 (8.5) 23 (9.3) 44 (8.9)
Arthralgia 30 (12.1) 11 (4.5) 41 (8.3)
Alanine aminotransferase increased 18 (7.3) 21 (8.5) 39 (7.9)
Urinary tract infection 21 (8.5) 16 (6.5) 37 (7.5)
Nail disorder 17 (6.9) 20 (8.1) 37 (7.5)
Aspartate aminotransferase
increased
13 (5.3) 22 (8.9) 35 (7.1)
Hyperglycemia 13 (5.3) 17 (6.9) 30 (6.1)
Bone pain 17 (6.9) 13 (5.3) 30 (6.1)
Headache 15 (6.1) 15 (6.1) 30 (6.1)
Cough 14 (5.7) 16 (6.5) 30 (6.1)
Dyspnea 13 (5.3) 16 (6.5) 29 (5.9)
Infusion-related reaction 17 (6.9) 11 (4.5) 28 (5.7)
Serious Adverse Eventsb
≥1 Serious adverse event 94 (38.1) 89 (36.2) 183 (37.1)
CTCAE preferred term
Neutropenia 68 (27.5) 62 (25.2) 130 (26.4)
Neutropenia with fever 11 (4.5) 10 (4.1) 21 (4.3)
Leukopenia 4 (1.6) 12 (4.9) 16 (3.2)
Pneumonia 4 (1.6) 5 (2.0) 9 (1.8)
Abbreviation: CTCAE, Common
Terminology Criteria for Adverse
Events.
a Treatment-emergent adverse
events by week 24 in more than 5%
of patients in either treatment
group, in descending order of
frequency in the overall safety
population.
b Serious adverse events, defined by
the investigator as grade 4 or
requiring hospitalization, by week
24 in at least 2% of patients in either
treatment group, in descending
order of frequency in the overall
safety population.
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the proposed biosimilar and 2.028 mg/kg/wk for trastu-
zumab). For part 1, the mean (SD) total exposure was 21.038
(6.4383) weeks for the proposed biosimilar and 20.327
(6.8221) weeks for trastuzumab. The mean (SD) number of
cycles received was 7.8 (2.13) for the proposed biosimilar
group and 7.5 (2.27) for the trastuzumab group.
Treatment-Emergent Adverse Events
The overall incidence of patients with at least 1 treatment-
emergent adverse event was 96.8% (n = 239) in the proposed
biosimilargroupand94.7%(n = 233) in the trastuzumabgroup.
The majority of events were mild or moderate in severity in
both treatment groups. In the safety population, a total of 14
participants (7 patients [2.8%] in each group) reported an ad-
verse event leading to discontinuation of treatment.
The incidence ratesof treatment-emergent adverseevents
of neutropenia, leukopenia, andanemiawere 57.5% (n = 142),
17.0% (n = 42), and 16.2% (n = 40), respectively, in the pro-
posedbiosimilar groupand53.3%(n = 131), 20.7%(n = 51), and
16.3% (n = 40), respectively, in the trastuzumab group. Ad-
verse events with Common Terminology Criteria for Adverse
Events grade 3 or higher were reported for 312 (63.3%) of all
participants,withneutropenia (221 patients [44.8%]) and leu-
kopenia (69 patients [14.0%]) the most frequently reported.
The most frequent nonhematologic treatment-emergent ad-
verse events inpatients in theproposedbiosimilar and trastu-
zumab groups, respectively, included peripheral neuropathy
(57 [23.1%] and 61 [24.8%]), diarrhea (51 [20.6%] and 51
[20.7%]), asthenia (54 [21.9%]and40 [16.3%]), andnausea (49
[19.8%]and34 [13.8%]).CommonTerminologyCriteria forAd-
verse Events grade 3 events were reported for less than 2% of
all participantswith thesenonhematologic events.Treatment-
emergent adverse events are summarized in Table 4.
Serious Adverse Events
The overall incidence of patients with at least 1 serious ad-
verse event (SAE)was 38.1% (n = 94) in the proposedbiosimi-
lar group and 36.2% (n = 89) in the trastuzumab group
(Table 4).
Only 4 SAE preferred terms were reported in at least 2%
in either treatment group (Table 4). Overall, the most fre-
quently reported SAE terms were neutropenia (130 patients
[26.4%]), febrile neutropenia (21 patients [4.3%]), and leuko-
penia (16 [3.2%]). No other SAEs were reported in at least 2%
of participants.
Eight participants (4 in each group) had SAEs that re-
sulted in death. One death due to respiratory failure in each
groupwas considered “possibly related” to studydrug. Other
adverse eventswith fatal outcomewere considered related to
taxane therapy, related to underlying or progressive disease,
or of unknown etiology.
Left Ventricular Ejection Fraction
The LVEF values at baseline in the proposed biosimilar group
(median, 64.0%; range, 51%-82%) and in the trastuzumab
group (median, 63.0%; range, 51%-84%) did not change ap-
preciably at week 24 (proposed biosimilar group: median,
−1.0%; range,−13%to21%; trastuzumabgroup:median,−1.0%;
range, −19% to 13%) (Table 5).
Immunogenicity
Fourteenparticipants (5.9%) in theproposedbiosimilar group
and21participants (8.9%) in the trastuzumabgroupwereposi-
tive for antidrug antibody prior to exposure to study treat-
ment. The number of patients with detectable antibody de-
clined over time.
Using a conservative approach that considers all patients
who tested positive for antidrug antibody at least once at any
timepointafterbaseline regardlessof theantidrugantibody re-
sult at baseline, the overall antidrug antibody rate was 2.4%
(6 of 245 patients) in the proposed biosimilar group and 2.8%
(7of246patients) in the trastuzumabgroup.Themeanandme-
dian titers forpatientswithpositive resultswere low(proposed
biosimilar group: mean, 3.2; median, 2.5; trastuzumab group:
mean, 2.0; median, 2.3). The highest titers reported at base-
line or any time after baseline (7.1 and 8.1, respectively, in the
proposed biosimilar group and 5.2 and 5.5, respectively, in
the trastuzumab group) confirmed low immunogenicity.
Discussion
Among women with ERBB2-positive metastatic breast can-
cer, the use of a proposed trastuzumab biosimilar compared
Table 5. Descriptive Statistics for Cardiac Function (LVEF Values) by Visit in the Safety Population
Visit and Statistic
LVEF, %
Proposed Biosimilar + Taxane
(n = 247)
Trastuzumab + Taxane
(n = 246)
Observed Change From Baseline Observed Change From Baseline
Baselinea,b (n = 246) (n = 244)
Mean (95% CI) 64.0 (63.3 to 64.7) 64.1 (63.4 to 64.8)
Median (range) 64.0 (51 to 82) 63.0 (51 to 84)
Week 12b (n = 212) (n = 212) (n = 209) (n = 207)
Mean (95% CI) 63.3 (62.4 to 64.1) −1.0 (−1.7 to −0.2) 63.4 (62.6 to 64.2) −0.8 (−1.5 to −0.2)
Median (range) 63.0 (28 to 79) −1.0 (−29 to 14) 63.0 (52 to 82) 0.0 (−16 to 14)
Week 24b (n = 148) (n = 148) (n = 140) (n = 138)
Mean (95% CI) 63.6 (62.8 to 64.4) −0.6 (−1.5 to 0.2) 63.2 (62.2 to 64.2) −0.9 (−1.8 to −0.1)
Median (range) 63.5 (50 to 81) −1.0 (−13 to 21) 63.0 (41 to 82) −1.0 (−19 to 13)
Abbreviation: LVEF, left ventricular
ejection fraction.
a Screening visit, prior to the first
dose of study drug.
b Sample sizes are the numbers of
patients with available data within
the treatment group.
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with trastuzumab, each combined with a taxane, resulted in
an equivalent ORR after 24 weeks of treatment; specifically,
the ORR was 69.6% (160 of 230 patients) (95% CI, 63.62%-
75.51%) for theproposedbiosimilar and64.0% (146of 228pa-
tients) (95% CI, 57.81%-70.26%) for trastuzumab.
Treatment with the anti-ERBB2 humanized monoclonal
antibody trastuzumab in combination with chemotherapy,
compared with chemotherapy alone, significantly improved
PFS and overall survival among patients with ERBB2-positive
metastatic breast cancer.14,15 However, trastuzumab is not
widely available around the world.4 A biosimilar treatment
option may increase global access to biological cancer thera-
pies, provided, among other issues, that the price of the bio-
similar is sufficiently inexpensive to enable women in non–
high-income countries to access this therapy.6,17,18
Abiosimilardrug is abiological product that ishighly simi-
lar to a licensed biological product, with no clinically mean-
ingfuldifferences in termsofsafety,purity,orpotency.19-21Con-
firmationofbiosimilarity isbasedonastepwiseprocessstarting
with analytical and nonclinical comparison of structural and
invitro functional characteristicsaswell as invivoanimal stud-
ies, including assessments of toxicity. The nature and extent
of data required for regulatory approval are determined on a
product-specific basis anddependon the level of evidenceob-
tained in the preceding steps.
This confirmatory efficacy and safety study was the last
step in the multistep process to demonstrate similarity of a
trastuzumab biosimilar and was adequately powered to dem-
onstrate equivalence with trastuzumab. Pertuzumab (a HER2
dimerization inhibitor) was not added to the treatment
groups in this study owing to the lack of worldwide availabil-
ity of this antibody; the equivalence comparison predated
pertuzumab approval.16 The results of this study are consis-
tent with the physicochemical and functional similarity
shown in vitro and in vivo and with the similar pharmacoki-
netics shown in healthy participants between the candidate
biosimilar and trastuzumab.11
At week 24, the ORR was 69.6% in the proposed trastu-
zumabbiosimilar groupand64.0% in the trastuzumabgroup.
Therapeutic equivalence of the proposed trastuzumab bio-
similar and trastuzumabwas statistically supportedby thepri-
mary efficacy as well as the results of sensitivity analysis in
the per protocol population. Additionally, the ORR data were
consistentwith thepublisheddata for trastuzumab.16,22,23 All
secondary efficacy analyses (TTP, PFS, and overall survival)
at week 24 and PFS and overall survival in patients followed
up for at least 48 weeks supported the conclusion of thera-
peutic equivalence.
There were no notable differences between the treat-
ment groups with regard to the type, incidence, or severity
of treatment-emergent adverse events or between the inci-
dence and type of SAEs reported. The population pharma-
cokinetic analysis was consistent with the findings from
studies in healthy volunteers11 that demonstrated similar
pharmacokinetics between the proposed biosimilar and
trastuzumab.
The immunogenicity profile was low, similar between
the 2 products and consistent with published data with
trastuzumab showing a low immunogenic potential. Base-
line positivity for antidrug antibody in a small number of
patients is expected. A similar positive rate was observed in
previous reports andmay be due to potential cross-reactivity
with preexisting antibodies and the test’s high sensitivity
level (previous trastuzumab treatments, high level of extra-
cellular domain).24,25 Potential interference of trastuzumab
with the antitrastuzumab antibody detection assay needs to
be considered when assessing the results from posttreat-
ment samples, although the assay was designed to minimize
these effects.
This studywas designed to assess efficacy and safety in a
biosimilar development program in which there is an under-
lyingpresumptionthatamoleculeshowntobestructurallyand
functionally highly similar to a reference product is antici-
pated to behave like the reference product in the clinical
setting.6 The limitations of this study are consistent with the
planned development of biosimilars, which uses short-term
efficacy end points as the final step in assessing biosimilarity.
The choice of the 24-week evaluation period for part 1 of this
studywas related to the ability to analyze the ORR as a short-
termmeasure of clinical activity and safety directly related to
the combination of taxanes with trastuzumab and the pro-
posed biosimilar as first-line treatment. This report includes
the 48-week TTP, PFS, and overall survival, which add to the
efficacy end point assessment. Ongoing follow-upwill assess
longer-termefficacyandsafety information toevaluate theuse
of theproposed trastuzumabbiosimilar aloneduring themain-
tenance phase.
Conclusions
Among women with ERBB2-positive metastatic breast can-
cer receiving taxanes, the use of a proposed trastuzumab bio-
similar comparedwith trastuzumab resulted in an equivalent
overall response rate at 24 weeks. Further study is needed to
assess safety and long-term clinical outcome.
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